Contraception
Volume 67, Issue 1 , Pages 25-32 , January 2003

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

  • I. Wiegratz

      Affiliations

    • Department of Obstetrics and Gynecology, J. W. Geothe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
    • ,
  • E. Kutschera

      Affiliations

    • Department of Obstetrics and Gynecology, J. W. Geothe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
    • ,
  • J.H. Lee

      Affiliations

    • Department of Obstetrics and Gynecology, J. W. Geothe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
    • ,
  • C. Moore

      Affiliations

    • Jenapharm GmbH & Co KG, Otto-Schott-Str. 15, D-07745 Jena, Germany
    • ,
  • U. Mellinger

      Affiliations

    • Jenapharm GmbH & Co KG, Otto-Schott-Str. 15, D-07745 Jena, Germany
    • ,
  • U.H. Winkler

      Affiliations

    • Department of Obstetrics and Gynecology, Kreiskrankenhaus Wetzlar, Forsthausstr. 1, D-35578 Wetzlar, Germany
    • ,
  • H. Kuhl

      Affiliations

    • Department of Obstetrics and Gynecology, J. W. Geothe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-69-63015692; fax: +49-69-63015522.

Received 28 February 2002 ,Revised 18 September 2002 ,Accepted 19 September 2002.

References 

  1. Larsson-Cohn U, Fahraeus L, Wallentin L, Zador G. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status. Acta Obstet Gynecol Scand. 1982;105(Suppl):S37–S40
  2. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction (results of the MICA case-control study). Br Med J. 1999;318:1579–1584
  3. Moore DE, Kawagoe S, Davajan V, Nakamura RM, Mishell DR. An in vivo system in man for quantitation of estrogenicity. II. Pharmacologic changes in binding capacity of serum corticosteroid-binding globulin induced by conjugated estrogens, mestranol, and ethinyl estradiol. Am J Obstet Gynecol. 1978;130:482–486
  4. Song S, Chen JK, He ML, Fotherby K. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin. Contraception. 1989;39:385–399
  5. Gurpide E, Marks C. Influence of endometrial 17β-hydroxysteroid dehydrogenase activity on the binding of estradiol to receptors. J Clin Endocrinol Metab. 1981;52:252–255
  6. Moore C, Elger W, Graeser T, Hoffmann H, Schwarz S, Zimmermann H. Different alternatives for the substitution of ethinylestradiol in oral contraceptives. In:  Kuhl H,  Nikolov R editor. Re-evaluation of contraceptive steroids. Bad Blankenburg: Harfe Verlag; 1998;p. 25–35
  7. Hoffmann H, Moore C, Zimmermann H, et al.  Approaches to the replacement of ethinylestradiol by natural 17β-estradiol in combined oral contraceptives. Exp Toxic Pathol. 1998;50:458–464
  8. Kuhl H. Ideal dose of ethinylestradiol. In:  Elstein M editors. Extragenital effects of oral contraceptives. Carnforth: Parthenon; 1997;p. 27–38
  9. Kuhl H. The clinical relevance of different progestins in oral contraceptives. In:  Kuhl H,  Nikolov R editor. Re-evaluation of contraceptive steroids. Bad Blankenburg: Harfe Verlag; 1998;p. 13–24
  10. Gruschke A, Kuhl H. Validity of radioimmunological methods for determining free testosterone in serum. Fertil Steril. 2001;76:576–582
  11. Serup J, Bostofte E, Larsen S, Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. Acta Obstet Gynecol Scand. 1981;60:203–206
  12. Hirvonen E, Allonen H, Anttila M, et al.  Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. 1995;21:27–32
  13. Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17β-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996;54:333–338
  14. Fraser IS, Hickey M. Endometrial vascular changes and bleeding disturbances with long-acting progestins. Steroids. 2000;65:665–670
  15. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 1987;156:199–203
  16. Refn H, Kjaer A, Lebech AM, Borggaard B, Schierup L. Clinical and hormonal effects of two oral contraceptives (correlations to serum concentrations of levonorgestrel and gestodene). Contraception. 1990;41:259–268
  17. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JHH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41:345–351
  18. Wiegratz I, Jung-Hoffmann , Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341–346
  19. Coenen CMH, Thomas CMG, Borm GF, Hollanders JMG, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53:171–176
  20. Jung-Hoffmann C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel (pharmacokinetics and pharmacodynamic parameters). Horm Res. 1991;36:238–246
  21. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception. 1988;38:593–603
  22. Schwartz U, Hammerstein J. The oestrogenic potency of various contraceptive steroids as determined by their effects on transcortin binding capacity. Acta Endocrinol. 1974;76:159–171
  23. Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel and levonorgestrel. Fertil Steril. 1984;42:44–51
  24. Jung-Hoffmann C, Storch A, Kuhl H. Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel. Horm Res. 1992;38:184–189
  25. Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception. 1993;47:55–68
  26. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation (a mechanism for estrogen-induced elevation of serum TBG concentration). J Clin Endocrinol Metab. 1987;65:689–696
  27. Dunn JF, Nisula BC, Rodbard S. Transport of steroid hormones (binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma). J Clin Endocrinol Metab. 1981;53:58–68
  28. Gaspard UJ, Romus MA, Gillain D, Franchimont P, Duvivier J. Plasma hormone levels in women receiving new oral contraceptives containing ethinylestradiol plus levonorgestrel and desogestrel. Contraception. 1983;27:577–590
  29. Gaspard UJ, Dubois M, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception. 1984;29:305–318
  30. Kuhnz W, Baumann A, Staks T, Dippelt L, Knuppen R, Jütting G. Pharmakokinetics of gestodene and ethinylestradiol in 14 women in three months of treatment with a new tri-step combination oral contraceptive (serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum). Contraception. 1993;48:303–322
  31. Kim-Börklund T, Landgren BM, Hamberger L. Is the contraceptive effect of 300 μg norethisterone mainly peripheral or central?. Contraception. 1992;45:57–66
  32. Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 1998;58:75–81
  33. Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol. 1978;51:541–544
  34. Kuhl H, Gahn G, Romberg G, März W, Taubert H-D. A randomized cross-over comparison of two low dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception. 1985;31:583–593
  35. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception. 1983;27:577–590
  36. Davis JRE, Selby C, Jeffcoate C. Oral contraceptive agent do not affect serum prolactin in normal women. Clin Endocrinol. 1984;20:427–434
  37. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception (a prospective study). Obstet Gynecol. 1985;63:506–510
  38. Abu-Fadil S, DeVane G, Siler TM, Yen SSC. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception. 1976;13:79–85
  39. Dericks-Tan JSE, Taubert HD. Elevation of serum prolactin during application of oral contraceptives. Contraception. 1976;14:1–8

PII: S0010-7824(02)00436-5

Contraception
Volume 67, Issue 1 , Pages 25-32 , January 2003

Article Tools

* Image Usage & Resolution